Barclays upgraded Grifols to Equal Weight from Underweight with a price target of EUR 13.50, up from EUR 9 after transferring coverage of the name. Boosted by plasma capacity investments over the past five years and now on the other side of COVID, the company should post strong growth from here, the firm tells investors in a research note. However, leverage remains a concern and competition looms, both near and longer term, adds Barclays.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on GRFS:
- Grifols price target lowered to EUR 17.80 from EUR 19.80 at Berenberg
- Grifols price target raised to EUR 16 from EUR 14 at Morgan Stanley
- Grifols upgraded to Buy from Add at AlphaValue/Baader
- Grifols upgraded to Buy from Hold at Jefferies
- Grifols price target lowered to EUR 8.50 from EUR 9 at JPMorgan
